Titre :

Daratumumab plus lenalidomide and dexamethasone for untreated myeloma

Auteur(s) :

Facon, Thierry [Auteur]
Kumar, Shaji [Auteur]
Plesner, Torben [Auteur]
Orlowski, Robert Z. [Auteur]
Moreau, Philippe [Auteur]
Bahlis, Nizar [Auteur]
Basu, Supratik [Auteur]
Nahi, Hareth [Auteur]
Hulin, Cyrille [Auteur]
Quach, Hang [Auteur]
Goldschmidt, Hartmut [Auteur]
O''''dwyer, Michael [Auteur]
Perrot, Aurore [Auteur]
Venner, Christopher P. [Auteur]
Weisel, Katja [Auteur]
Mace, Joseph R. [Auteur]
Raje, Noopur [Auteur]
Attal, Michel [Auteur]
Tiab, Mourad [Auteur]
Macro, Margaret [Auteur]
Frenzel, Laurent [Auteur]
Leleu, Xavier [Auteur]
Ahmadi, Tahamtan [Auteur]
Chiu, Christopher [Auteur]
Wang, Jianping [Auteur]
Van Rampelbergh, Rian [Auteur]
Uhlar, Clarissa M. [Auteur]
Kobos, Rachel [Auteur]
Qi, Ming [Auteur]
Usmani, Saad Z. [Auteur]

Titre de la revue :

The New England journal of medicine

Nom court de la revue :

N. Engl. J. Med.

Numéro :

380

Pagination :

2104-2115

Date de publication :

2019-05-30

ISSN :

1533-4406

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab ...
Lire la suite >Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or death in this population. We randomly assigned 737 patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation to receive daratumumab plus lenalidomide and dexamethasone (daratumumab group) or lenalidomide and dexamethasone alone (control group). Treatment was to continue until the occurrence of disease progression or unacceptable side effects. The primary end point was progression-free survival. At a median follow-up of 28.0 months, disease progression or death had occurred in 240 patients (97 of 368 patients [26.4%] in the daratumumab group and 143 of 369 patients [38.8%] in the control group). The estimated percentage of patients who were alive without disease progression at 30 months was 70.6% (95% confidence interval [CI], 65.0 to 75.4) in the daratumumab group and 55.6% (95% CI, 49.5 to 61.3) in the control group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.43 to 0.73; P<0.001). The percentage of patients with a complete response or better was 47.6% in the daratumumab group and 24.9% in the control group (P<0.001). A total of 24.2% of the patients in the daratumumab group, as compared with 7.3% of the patients in the control group, had results below the threshold for minimal residual disease (1 tumor cell per 105 Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T16:50:09Z